Skip to content
★ Sign in to follow
VI

Vyyo Inc Stock: price and insider trades · United States

No insider purchase over the last 90 days. The latest, by GOLDMAN SACHS GROUP INC/, was filed 20 Sept 2007.

Vyyo Inc: what insiders have been doing

This page follows insider dealings at Vyyo Inc as filed with SEC (Form 4). No insider at Vyyo Inc has published a filing in the past twelve months. The most recent one dates from 11 December 2007.

Looking back to 2006, when coverage begins, insiders filed 8 purchases and 2 sales.

Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Insider Decl.
38
Thresholds
n/a
Buy Volume
€47,579
8 ops. · all time
Sell Volume
€4M
2 ops. · all time

Financial data

· cache

Last declaration on 11 December 2007
Declarations38 total
  • ▼
    Related company / holdingExecutives
    7M USD0SEC
    1,651,982 shares@ US$3.97Common StockSEC:0000769993-07-001105:0
  • ◇
    EVP Corp Strategy & Inv RelExecutives
    1,000 USD0SEC
    10,000 shares@ US$0.10Common StockSEC:0001373672-07-000008:0
  • ◇
    DirectorExecutives
    4,101 USD0SEC
    1,667 shares@ US$2.46Common StockSEC:0001007482-07-000009:0
  • ◇
    DirectorExecutives
    4,101 USD0SEC
    1,667 shares@ US$2.46Common StockSEC:0001240506-07-000009:0
  • ◇
    DirectorExecutives
    4,101 USD0SEC
    1,667 shares@ US$2.46Common StockSEC:0001239512-07-000011:0
  • ◇
    DirectorExecutives
    4,101 USD0SEC
    1,667 shares@ US$2.46Common StockSEC:0001240086-07-000011:0
  • ▼
    Related company / holdingExecutives
    7,224 USD0SEC
    1,400 shares@ US$5.16Common StockSEC:0000769993-07-000956:0
  • ▲
    Related company / holdingExecutives
    921 USD0SEC
    170 shares@ US$5.42Common StockSEC:0000769993-07-000956:1
    Canonical exit: 18 Dec 2007 (T+90)
  • ▲
    Related company / holdingExecutives
    2,156 USD0SEC
    400 shares@ US$5.39Common StockSEC:0000769993-07-000956:2
    Canonical exit: 18 Dec 2007 (T+90)
  • ▲
    Related company / holdingExecutives
    538 USD0SEC
    100 shares@ US$5.38Common StockSEC:0000769993-07-000956:3
    Canonical exit: 18 Dec 2007 (T+90)
  • ▲
    Related company / holdingExecutives
    537 USD0SEC
    100 shares@ US$5.37Common StockSEC:0000769993-07-000956:4
    Canonical exit: 18 Dec 2007 (T+90)
  • ▲
    Related company / holdingExecutives
    1,233 USD0SEC
    230 shares@ US$5.36Common StockSEC:0000769993-07-000956:5
    Canonical exit: 18 Dec 2007 (T+90)
  • ▲
    Related company / holdingExecutives
    2,132 USD0SEC
    400 shares@ US$5.33Common StockSEC:0000769993-07-000956:6
    Canonical exit: 18 Dec 2007 (T+90)
  • ●
    DirectorExecutives
    0SEC
    75,000 shares0Common StockSEC:0000939286-07-000009:0
  • ◇
    DirectorExecutives
    4,168 USD0SEC
    1,667 shares@ US$2.50Common StockSEC:0001239512-07-000009:0
  • ◇
    DirectorExecutives
    4,168 USD0SEC
    1,667 shares@ US$2.50Common StockSEC:0001240506-07-000006:0
  • ◇
    DirectorExecutives
    4,168 USD0SEC
    1,667 shares@ US$2.50Common StockSEC:0001240086-07-000008:0
  • ●
    DirectorExecutives
    0SEC
    418,286 shares0Common StockSEC:0000939286-07-000007:0
  • ◇
    DirectorExecutives
    4,168 USD0SEC
    1,667 shares@ US$2.50Common StockSEC:0001007482-07-000005:0
  • ◇
    DirectorExecutives
    5,951 USD0SEC
    1,667 shares@ US$3.57Common StockSEC:0001007482-07-000005:1
  • ◇
    DirectorExecutives
    5,951 USD0SEC
    1,667 shares@ US$3.57Common StockSEC:0001239512-07-000006:0
  • ◇
    DirectorExecutives
    5,951 USD0SEC
    1,667 shares@ US$3.57Common StockSEC:0001240086-07-000004:0
  • ◇
    DirectorExecutives
    5,951 USD0SEC
    1,667 shares@ US$3.57Common StockSEC:0001240506-07-000004:0
  • ◇
    DirectorExecutives
    7,251 USD0SEC
    1,667 shares@ US$4.35Common StockSEC:0001239512-07-000002:0
  • ◇
    VP Corp Comm & Invest RelationExecutives
    1,000 USD0SEC
    10,000 shares@ US$0.10Common StockSEC:0001373672-06-000011:0

25 of 38 declarations

About Vyyo Inc

Vyyo Inc is a NASDAQ-listed company focused on developing treatments for viral diseases. It emphasizes innovation in the biotechnology sector.